Roivant highlights continued pipeline progress and outlook

Switzerland-based Roivant (Nasdaq: ROIV) hosted an Investor Day in New York City today, highlighting its leadership with key pipeline updates and provided an update on the company’s strategy for long-term value creation, which saw the firm’s shares rise 6.6% to $21.58 in morning trading.

“We are at transformational moment for Roivant. We have a unique opportunity to execute on three major potential products, each of which represents a pipeline-in-a-product opportunity, each with multiple blockbuster-potential indications. I’m proud of the clinical execution across our teams, and we have accelerated timing guidance for top-line readouts in three significant programs. We have an opportunity for three meaningful first-in-class commercial launches over the next three years,” said Matt Gline, chief executive of Roivant.

“First among them is brepocitinib in DM, where the Phase III data generated earlier this year represents a significant step forward for patients in need. We remain well-positioned to generate shareholder value, and we are excited to share updates across our late-stage pipeline and long-term strategy at our Investor Day today,” he added.